DR. LAKSHMIKANTH KATRAGADDA M.D. NPI 1336303940

NPI Details

DR. Lakshmikanth Katragadda, M.D. is a hematology and oncology internal medicine in Huntsville, AL with 23 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. DR. Lakshmikanth Katragadda, M.D. NPI is 1336303940. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

The provider's business location address is:

3601 CCI DR NW
HUNTSVILLE, AL
ZIP 35805-606
Phone: (256) 705-4224

The NPI 1336303940 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, levoleucovorin (khapzory), 0.5 mg (HCPCS:J0642)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1568)
• Injection, ferric derisomaltose, 10 mg (HCPCS:J1437)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, docetaxel, 1 mg (HCPCS:J9171)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, pegfilgrastim-apgf, biosimilar, (nyvepria), 0.5 mg (HCPCS:Q5122)
• Injection, iron dextran, 50 mg (HCPCS:J1750)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Ferritin (blood protein) level (HCPCS:82728)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Red blood count automated, with additional calculations (HCPCS:85046)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Folic acid level, serum (HCPCS:82746)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Flow cytometry technique for dna or cell analysis, each additional marker (HCPCS:88185)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Nephelometry, test method using light (HCPCS:83883)
• Injection, potassium chloride, per 2 meq (HCPCS:J3480)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Magnesium level (HCPCS:83735)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Beta-2 microglobulin (protein) level (HCPCS:82232)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Phosphate level (HCPCS:84100)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Unclassified drugs (HCPCS:J3490)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Injection, fosnetupitant 235 mg and palonosetron 0.25 mg (HCPCS:J1454)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Protein measurement, serum (HCPCS:84165)
• Automated urinalysis test (HCPCS:81003)
• Red blood cell sedimentation rate, to detect inflammation, automated (HCPCS:85652)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Initial hospital inpatient care per day, typically 50 minutes (HCPCS:99222)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 19-9 (HCPCS:86301)
• Vitamin d-3 level (HCPCS:82306)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Thyroxine (thyroid chemical), free (HCPCS:84439)
• Urine volume measurement (HCPCS:81050)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 125 (HCPCS:86304)
• Injection of drug or substance into vein (HCPCS:96374)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Coagulation function measurement, qualitative or semiquantitative (HCPCS:85378)
• Total protein level, urine (HCPCS:84156)
• Flow cytometry technique for dna or cell analysis, first marker (HCPCS:88184)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Erythropoietin (protein) level (HCPCS:82668)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Follow-up hospital inpatient care per day, typically 15 minutes (HCPCS:99231)
• Translocation analysis (bcr/abl1) major breakpoint (HCPCS:81206)
• Translocation analysis (bcr/abl1) minor breakpoint (HCPCS:81207)
• Biopsy and aspiration of bone marrow sample for diagnosis (HCPCS:38222)
• Immunologic analysis technique on serum (immunofixation) (HCPCS:86334)
• Protein measurement, body fluid (HCPCS:84166)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Administration of influenza virus vaccine (HCPCS:G0008)
• Established patient office or other outpatient visit, 10-19 minutes (HCPCS:99212)
• Influenza vaccine, quadrivalent derived from cell cultures, preservative and antibiotic free (HCPCS:90674)
• Gene analysis (janus kinase 2) variant (HCPCS:81270)

The enumeration date for this NPI number is 7/12/2008 and was last updated on 1/27/2023.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: